The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNA-Based Therapeutics and Vaccines Market Research Report 2024
Synopsis
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The global RNA-Based Therapeutics and Vaccines market was valued at US$ 25 million in 2023 and is anticipated to reach US$ 634.8 million by 2030, witnessing a CAGR of 57.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Based Therapeutics and Vaccines.
Report Scope
The RNA-Based Therapeutics and Vaccines market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA-Based Therapeutics and Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA-Based Therapeutics and Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Segment by Type
RNA-Based Therapeutics
RNA-Based Vaccines
Segment by Application
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The global RNA-Based Therapeutics and Vaccines market was valued at US$ 25 million in 2023 and is anticipated to reach US$ 634.8 million by 2030, witnessing a CAGR of 57.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Based Therapeutics and Vaccines.
Report Scope
The RNA-Based Therapeutics and Vaccines market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA-Based Therapeutics and Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA-Based Therapeutics and Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Segment by Type
RNA-Based Therapeutics
RNA-Based Vaccines
Segment by Application
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 RNA-Based Therapeutics
1.2.3 RNA-Based Vaccines
1.3 Market by Application
1.3.1 Global RNA-Based Therapeutics and Vaccines Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Immunology
1.3.4 Ophthalmology
1.3.5 Cardiovascular Diseases
1.3.6 Infectious Diseases
1.3.7 Genetic Diseases
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNA-Based Therapeutics and Vaccines Market Perspective (2019-2030)
2.2 RNA-Based Therapeutics and Vaccines Growth Trends by Region
2.2.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNA-Based Therapeutics and Vaccines Historic Market Size by Region (2019-2024)
2.2.3 RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2025-2030)
2.3 RNA-Based Therapeutics and Vaccines Market Dynamics
2.3.1 RNA-Based Therapeutics and Vaccines Industry Trends
2.3.2 RNA-Based Therapeutics and Vaccines Market Drivers
2.3.3 RNA-Based Therapeutics and Vaccines Market Challenges
2.3.4 RNA-Based Therapeutics and Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue
3.1.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue (2019-2024)
3.1.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Players (2019-2024)
3.2 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA-Based Therapeutics and Vaccines Revenue
3.4 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio
3.4.1 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA-Based Therapeutics and Vaccines Revenue in 2023
3.5 RNA-Based Therapeutics and Vaccines Key Players Head office and Area Served
3.6 Key Players RNA-Based Therapeutics and Vaccines Product Solution and Service
3.7 Date of Enter into RNA-Based Therapeutics and Vaccines Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA-Based Therapeutics and Vaccines Breakdown Data by Type
4.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Type (2019-2024)
4.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2025-2030)
5 RNA-Based Therapeutics and Vaccines Breakdown Data by Application
5.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Application (2019-2024)
5.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America RNA-Based Therapeutics and Vaccines Market Size (2019-2030)
6.2 North America RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024)
6.4 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNA-Based Therapeutics and Vaccines Market Size (2019-2030)
7.2 Europe RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024)
7.4 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size (2019-2030)
8.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2019-2024)
8.4 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNA-Based Therapeutics and Vaccines Market Size (2019-2030)
9.2 Latin America RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024)
9.4 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size (2019-2030)
10.2 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024)
10.4 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Detail
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction
11.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.2.5 Arbutus Biopharma Recent Development
11.3 Arrowhead Pharmaceuticals
11.3.1 Arrowhead Pharmaceuticals Company Detail
11.3.2 Arrowhead Pharmaceuticals Business Overview
11.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.3.5 Arrowhead Pharmaceuticals Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction
11.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 CureVac
11.5.1 CureVac Company Detail
11.5.2 CureVac Business Overview
11.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction
11.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.5.5 CureVac Recent Development
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Company Detail
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.6.5 Dicerna Pharmaceuticals Recent Development
11.7 Regulus Therapeutics
11.7.1 Regulus Therapeutics Company Detail
11.7.2 Regulus Therapeutics Business Overview
11.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.7.5 Regulus Therapeutics Recent Development
11.8 Marina Biotech
11.8.1 Marina Biotech Company Detail
11.8.2 Marina Biotech Business Overview
11.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction
11.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.8.5 Marina Biotech Recent Development
11.9 MiRagen Therapeutics
11.9.1 MiRagen Therapeutics Company Detail
11.9.2 MiRagen Therapeutics Business Overview
11.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.9.5 MiRagen Therapeutics Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Detail
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.10.5 Moderna Therapeutics Recent Development
11.11 Quark Pharmaceuticals
11.11.1 Quark Pharmaceuticals Company Detail
11.11.2 Quark Pharmaceuticals Business Overview
11.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.11.5 Quark Pharmaceuticals Recent Development
11.12 Roche
11.12.1 Roche Company Detail
11.12.2 Roche Business Overview
11.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction
11.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.12.5 Roche Recent Development
11.13 Sylentis
11.13.1 Sylentis Company Detail
11.13.2 Sylentis Business Overview
11.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction
11.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024)
11.13.5 Sylentis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
